However, these cells maintain active the same VEGFA-activated pathways by the upregulation of others alternative TRK receptor ligands (i.e. FGF2, PDGFD and KITLG) that have been implicated in the development and drug resistance in other cancer types (82–84). This evidence concerns the gene FGF2 and cancer.